IL9 and ovarian cancer: These results clearly point to a clinically beneficial IFNγ – p40/IL12B axis in differentiating myeloid cells in the ovarian cancer microenvironment, thus providing a potential explanation for the association of subgroup B TAMs with clinically favorable parameters.